-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Receives Notice Of Allowance From Brazilian Patent Office For Issuance Of Patent For Additional Opioid Families For Company's Trypsin Activated Abuse Protection, Multi-Pill Abuse Resistance Technologies

Benzinga·01/21/2026 13:09:18
Listen to the news

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent* covering additional opioid families, utilizing the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.

The newly allowed patent includes both composition of matter and method of use claims, further strengthening Ensysce's intellectual property estate and expanding its global protection for Next Generation analgesics. This patent builds on the protection Ensysce has around additional opioid families not only in North America but also in the EU and South America.